Alcon Inc. Q2 FY2025 earnings call

• Business Development: Acquired STAAR for $1.5 billion to strengthen refractive surgery offering; acquired LumiThera and its Valeda Light Delivery System for dry AMD. - Product Launches: Unity VCS, a next-generation combined vitreoretinal cataract system, began shipping in May with a strong order book. PanOptix Pro, a trifocal IOL, shows solid adoption trends. Precision7 contact lenses advance in the U.S. Tryptyr, a prescription eye drop for dry eye, launched in late July. - Operational Updates: Continues to invest in R&D, with full year R&D expected to be in the top half of 8%-10% of sales range.

Surgical Franchise: Revenue was $1.5 billion, up 1% year-over-year. Implantable sales were $456 million, down 2% year-over-year. Consumables sales were $777 million, up 4% year-over-year. Equipment sales were $222 million, down slightly. Vision Care: Sales were $1.1 billion, up 5% year-over-year. Contact lens sales were $692 million, up 7% year-over-year. Ocular Health: Sales were $430 million, up 2% year-over-year.

• Full-year revenue guidance updated to $10.3 billion to $10.4 billion, with constant currency growth between 4% and 5%. - Core operating margin expected to be between 19.5% and 20.5%. - Core diluted earnings guidance range maintained at $3.05 to $3.15 per share, corresponding to 0%-2% year-over-year change in constant currency.

• Tariff-related charges: Incurred $27 million in Q2, with full-year impact expected at ~$100 million to cost of sales. - Macroeconomic headwinds in China affecting certain segments. - Competitive pressures in IOL and other market segments.

Q: Jeff Johnson asked about PC-IOL share in the U.S. and AT-IOL share outside the U.S.

A: David Endicott noted PanOptix Pro's positive performance in the U.S. but mentioned international pressure with new competitors.

Q: Jack Reynolds-Clark inquired about market weakness and Unity's order book.

A: David Endicott cited normalization of surgical procedure volumes and positive uptake of Unity VCS with a strong order book.

Q: Anthony Petrone asked about IOL stabilization and STAAR acquisition.

A: David Endicott discussed ongoing competition in IOL space and details on STAAR acquisition including China market and collamer material potential.

Q: Veronika Dubajova asked about Unity's placement and equipment outlook.

A: David Endicott provided insights on Unity's placement progress and equipment growth potential.

Q: Richard Felton asked about Systane performance and STAAR China.

A: David Endicott reported Systane's growth and discussed STAAR's China market importance.

Q: Christopher Pasquale asked about STAAR revenue growth and tariffs.

A: Timothy Stonesifer discussed tariff impact and mitigation, while David Endicott spoke on STAAR's revenue growth potential.

Q: Ryan Zimmerman asked about long-term targets and margins.

A: Timothy Stonesifer and David Endicott discussed long-term megatrends and margin trajectory with operating leverage expectations.

Q: Issie Kirby asked about contact lens market and Precision7.

A: David Endicott provided insights on contact lens market dynamics and Precision7's performance.

Q: Susannah Ludwig asked about consumables and price contribution.

A: David Endicott discussed subdued consumables growth and similar trends going forward.